Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO) announced promising preclinical data for its SHP2 inhibitor, BBP-398, targeting non-small cell lung cancer (NSCLC). The data, presented at the AACR-NCI-EORTC Conference, reveals BBP-398's potential as a combination agent with KRAS and EGFR inhibitors. The company is advancing a Phase 1 trial for patients with solid tumors with MAPK pathway mutations. The anticipated continuous once-daily dosing and strong preclinical efficacy could position BBP-398 as a leading treatment option for RAS-driven cancers. Further insights will be shared at the virtual R&D Day on October 12, 2021.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) will hold its second R&D Day on October 12, 2021, at 8:30 a.m. ET, showcasing its pipeline and new programs. The event will feature key executives, including founder and CEO Neil Kumar, discussing 14 clinical programs and over 30 total pipeline programs targeting genetic diseases and cancers. A focus will be on acoramidis, an investigational therapy for transthyretin amyloidosis (ATTR), with topline results expected in late 2021 and 2023. The webcast will be accessible through BridgeBio's investor website.
BridgeBio Pharma (Nasdaq: BBIO) reported updated results from its ongoing Phase 2b study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). The study involved 13 participants, with encaleret normalizing mean blood calcium levels and 24-hour urine calcium excretion within five days. No serious adverse events were reported, showcasing the drug's tolerability. The company plans to engage regulatory authorities for a Phase 3 study, aiming to develop the first approved therapy for ADH1. The ongoing research highlights a significant unmet medical need in this rare condition.
BridgeBio Pharma (Nasdaq: BBIO) announced that the FDA has granted Fast Track designation for BBP-418, aimed at treating Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This designation will expedite the development and review process for the therapy, addressing a critical unmet medical need for patients with this rare genetic condition. With 7,000 patients affected by LGMD2i, BBP-418 represents a significant advancement in BridgeBio's pipeline, which includes multiple ongoing programs in genetic diseases and cancers.
BridgeBio Pharma announced on September 2, 2021, the granting of restricted stock units totaling 61,210 shares to 29 new employees. This initiative aims to incentivize new hires and is in accordance with Nasdaq Listing Rule 5635(c)(4). These awards were made under the 2019 Inducement Equity Plan, which was approved in November 2019. BridgeBio focuses on developing transformative medicines for genetic diseases and cancers, with over 30 development programs currently in progress.
LianBio and BridgeBio Pharma announced the treatment of the first patient in a Phase 2a clinical trial of infigratinib for gastric cancer with FGFR2 gene amplification in China. This study is critical due to China's high gastric cancer prevalence. Infigratinib, an FGFR inhibitor, is already approved in the U.S. for cholangiocarcinoma and is being evaluated for other cancers. The trial's primary endpoint is objective response rate, with significant implications for treatment options in Asia.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the addition of three independent directors to its board: Fred Hassan, a veteran of the pharmaceutical industry; Andrea Ellis, CFO of Lime; and Douglas Dachille, former CIO of AIG. These appointments aim to enhance BridgeBio's strategic direction and expand its commercial infrastructure as it advances therapies for genetic diseases. CEO Neil Kumar expressed confidence that their diverse expertise will strengthen the company's mission. BridgeBio, founded in 2015, is focused on innovative therapies for patients with genetic conditions.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported second-quarter financial results for the period ending June 30, 2021, with total revenues of $54.0 million. The company achieved its second FDA approval for TRUSELTIQ™ (infigratinib) for cholangiocarcinoma, a significant milestone. Operating costs rose to $148.0 million due to increased personnel and stock-based compensation, leading to a net loss of $102.1 million. Cash and cash equivalents totaled $898.4 million, highlighting a strong liquidity position despite rising expenses.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the granting of 21,414 restricted stock units to 17 new employees on August 3, 2021. This issuance is part of the company's 2019 Inducement Equity Plan, ensuring compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing innovative treatments for genetic diseases and cancers. The company has over 30 programs in its pipeline, aiming to expedite the delivery of its first approved therapy.
BridgeBio Pharma has announced a non-exclusive collaboration with Bristol Myers Squibb to evaluate BBP-398, a promising SHP2 inhibitor, in combination with OPDIVO® for treating advanced solid tumors with KRAS mutations. The collaboration includes a Phase 1/2 trial assessing the safety and efficacy of BBP-398 alongside OPDIVO as doublet therapy and with a KRASG12C inhibitor as triplet therapy in non-small cell lung cancer. Both companies will co-fund the clinical development activities. BRIDGE Bio aims to provide new treatment options for patients with difficult-to-treat cancers.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
